We are pleased to expand commercial access to QUELIMMUNE and are extremely proud to be the only company to develop and commercialize a therapeutic device that has demonstrated clinical results to ...
This study addresses fundamental questions surrounding otitis media effusion in Down syndrome, identifying DYRK1A as a key gene involved in the condition. The findings are compelling, highlighting ...